About: Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2, which is in phase 2a trial for the treatment of ulcerative colitis; OD-002, an oral small molecule SLC15A4 inhibitor designed to block TLR7/8/9-mediated pathogenic inflammatory responses activation of interferon regulatory factor 5 (IRF5); OD-003, a protein therapeutic designed to agonize tumor necrosis factor receptor 2 selectively on Treg; a TSLP/IL-33 bispecific antagonist; an oral small molecule interleukin-1 receptor"associated kinase 4 scaffolding inhibitor; and a small molecule inhibitor of IRF5. The company was incorporated in 2021 and is headquartered in Boston, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Latest price: $18.08 (-0.28%)
ODTX NASDAQ Odyssey Therapeutics, Inc. Common Stock
Odyssey Therapeutics, Inc. Common Stock share price
ODTX price activity
Último preço
$ 18,080
Variação (24h)
-0,05 USD (-0,28%)
Volume
264.03K
Volume (média 4 sem.)
-
Abertura
$ 18,01
Variação do dia
$ 17,83 - $ 18,84
Fechamento anterior
$ 18,13
Último negócio
07 Oct, 8:00 pm GMT+0
Atrasado
07 Oct, 8:00 pm GMT+0
ODTX price performance
Atrasado
07 Oct, 8:00 pm GMT+0
quote.marketSignals